SCHEMBL4639754

SCHEMBL4639754

C=CCn1cc(C(=O)O)c(C)c1-c1ccccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
P2RX7 Q99572 1/20 0.38
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.36
CYP1A2 P05177 2/20 0.36
HPGD P15428 2/20 0.36
LMNA P02545 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
USP2 O75604 1/20 0.36
MT-CO2 P00403 1/20 0.36
TTR P02766 1/20 0.36
PLA2G1B P04054 1/20 0.36
PGR P06401 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638953 0.82 NR3C2 (0.44) KMT2AP2RX7ALDH1A1MEN1CYP1A2
SCHEMBL4639622 0.79 CNR1 (0.46) KMT2AP2RX7ALDH1A1MAPT
SCHEMBL1379303 0.79 NOTUM (0.39) KMT2AP2RX7ALDH1A1MEN1CYP1A2
SCHEMBL1383585 0.78 NR3C2 (0.57) KMT2AALDH1A1MEN1CYP2C19NPC1
SCHEMBL4639146 0.78 KMT2A (0.38) KMT2AP2RX7ALDH1A1MEN1CYP1A2
SCHEMBL4638567 0.76 AVPR2 (0.45) KMT2AP2RX7NOTUM
SCHEMBL4638388 0.75 RAB9A (0.40) KMT2AP2RX7ALDH1A1MEN1RAB9A
SCHEMBL4639246 0.74 KDM4E (0.42) KMT2AP2RX7ALDH1A1MEN1HPGD
SCHEMBL4638407 0.74 KDM4E (0.41) KMT2AP2RX7ALDH1A1MEN1RAB9A
SCHEMBL2445906 0.74 KDM4E (0.40) KMT2AP2RX7ALDH1A1DHODHEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 KMT2A 4657/4885P2RX7 244/4885ALDH1A1 2251/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 KMT2A 4657/4885P2RX7 244/4885ALDH1A1 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.